Cytori Therapeutics (CYTX) has appointed Steven Kesten, MD, as Executive Vice President and Chief Medical Officer. In this role, Dr. Kesten will lead global clinical development operations and Cytori’s Medical Affairs activities.
“Dr. Kesten is a seasoned physician executive with more than 30 years of experience in medicine,” said Dr. Hedrick. “This experience includes involvement in high profile clinical trials, leading medical affairs activities, and navigating complex reimbursement environments. Dr. Kesten’s contributions will further strengthen our clinical program, starting with our cardiovascular business and extending to future therapeutic areas.”
Most recently Dr. Kesten served as Vice President and Chief Medical Officer at Uptake Medical, where he oversaw the completion of the VAPOR trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical’s device, InterVapor®. He previously served for more than ten years at Boehringer Ingelheim, most recently as the Vice President in Medicine for Marketed Products for respiratory disease. During his tenure, Dr. Kesten was responsible for the development and execution of multiple large-scale clinical trials and took the medical lead in the global registration, branding and reimbursement of the drug Spiriva®, a $3 billion worldwide product for chronic obstructive pulmonary disease. Dr. Kesten lived in Germany for three years and is experienced in European regulatory affairs and reimbursement strategies.
In addition, Dr. Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St. Luke’s Medical Center in Chicago. Dr. Kesten received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.
They hired this guy to be a rainmake,r directly related to capitalizing on the EU approval of Intravese. I'm sure we will hear more about the plans on the cc next week. He had better hit the ground running.
Hope he provides more of a service to the company then Clyde Shores has. So now the focus is back on europe, it doesn't get any more confusing then trying to keep up with the changes in strategy at Cytori. and management still remains silent. Ughhh!!
another guy who gets to much options and a lot of money this company don´t have. More guys in management and the shareprice will going down down down (would have been better they would have fired clahoun instead of inflate the management-loosergroup)